ArticleJournal of cosmetic dermatology2025
Effectiveness of an Autologous Micrografting Technology for Treating Stretch Marks.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness of an Autologous Micrografting Technology for Treating Stretch Marks.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStretch marks or striae distensae (SD) are common dermal lesions caused by the disruption of collagen and elastin fibers in the skin, often triggered by rapid mechanical stretching. Despite the availability of numerous treatment modalities, from topical agents to energy-based devices, no single therapy has demonstrated consistent, long-term efficacy across all patient populations. The pathophysiology of SD involves complex alterations in the extracellular matrix (ECM), particularly affecting fibroblast activity and collagen/elastin synthesis.
aimsThis pilot study aims to evaluate the clinical and molecular efficacy of autologous micrografting technology as a novel therapeutic option for SD. Specifically, it investigates the treatment's impact on ECM-related gene expression and overall skin appearance. PATIENTS/
methodsFourteen patients (13 females, 1 male) with clinically evident SD were enrolled. All participants underwent a standardized treatment protocol comprising microneedling followed by intradermal injection of autologous micrografts, obtained via a minimally invasive procedure. Clinical assessments were performed through standardized photography at baseline, 1 month, and 6 months post-treatment. In vitro assays were conducted on cultured human dermal fibroblasts exposed to the micrograft suspension.
resultsClinical evaluations showed noticeable aesthetic improvements, including reduced striae visibility and improved skin texture, with high patient-reported satisfaction. Molecular analyses revealed the upregulation of key ECM genes, including COL4A1, COL6A1, and ELN, indicating enhanced fibroblast activation and regenerative potential.
conclusionsAutologous micrografting appears to be a promising, biologically active approach for SD treatment. It promotes ECM remodeling by stimulating fibroblast function and may represent a valuable addition to the therapeutic landscape for stretch marks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.